Stock CRL * CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Charles River Laboratories International, Inc. Mexican S.E.

Equities

CRL *

US1598641074

End-of-day quote Mexican S.E.
Other stock markets
 18:00:00 2024-06-09 EDT 		5-day change 1st Jan Change
3,917 MXN -3.26% Intraday chart for Charles River Laboratories International, Inc. -3.26% +0.20%
06-13 Baird Adjusts Price Target on Charles River Laboratories International to $271 From $270 MT
06-07 The job report just threw a spanner in the works Our Logo

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company's earnings growth outlook lacks momentum and is a weakness.
  • With a 2024 P/E ratio at 26.34 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
  • Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
+0.20% 10.79B -
MODERNA, INC. Stock Moderna, Inc.
+40.80% 53.67B
B-
LONZA GROUP AG Stock Lonza Group AG
+35.79% 38.86B
A
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.05% 38.76B
B
CELLTRION, INC. Stock Celltrion, Inc.
-8.98% 27.27B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.69% 25.91B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-16.21% 20.29B
B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+31.00% 12.78B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.51% 12.18B
C+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-1.67% 11.96B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. CRL Stock
  4. CRL * Stock
  5. Ratings Charles River Laboratories International, Inc.